Clinical Trial Detail

NCT ID NCT02721433
Title 4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases (REaCT-BTA)
Recruitment Active, not recruiting
Gender both
Phase FDA approved
Variant Requirements No
Sponsors Ottawa Hospital Research Institute
Indications

prostate cancer

breast cancer

Therapies

Denosumab + pamidronate + Zoledronic acid

Age Groups: adult senior

No variant requirements are available.